Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with ...

That takes CTLA4 inhibition into uncharted territory in HCC, as BMS' Yervoy plus Opdivo is FDA-approved only as a second-line treatment after sorafenib, sold by Bayer as Nexavar and also available ...

Approval would make an Opdivo regimen an option for HCC again after the drug was pulled from the market in 2021 as a second-line treatment in people previously treated with Bayer's Nexavar ...

Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...

Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

While traditional chemotherapy has been less effective for liver cancer, targeted therapy drugs like sorafenib (Nexavar) have shown promise in treating HCC by specifically stopping the cancer cells ...